Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Products>This Product
  Products


OverExpress C41(DE3) Chemically Competent Cells - 24 reactions

Product Description
Express genes cloned into any T7 vector with these BL21(DE3) derivatives
Effective in expressing toxic & membrane proteins
Cited in over 350 research articles

E. coli BL21(DE3) strains, like Lucigen’s E. cloni® EXPRESS Competent Cells provide reliable expression of many genes cloned into T7 expression vectors (e.g., pET or Lucigen’s pSMART®-cDNA vectors). However, in some cases expression is minimal or not detectable because the recombinant protein, when expressed, is deleterious or lethal to these standard BL21 strains. Examples of such toxic proteins include many membrane proteins, some cytoplasmic proteins, and nucleases. Unfortunately, successful expression of one or more toxic proteins is often important to the experimental goal.

Lucigen’s OverExpress Electrocompetent and Chemically Competent Cells are E. coli strains that are effective in expressing toxic proteins from all classes of organisms, including eubacteria, yeasts, plants, viruses, and mammals. The effectiveness of these new strains in expressing toxic proteins has been validated in more than 350 publications.

The OverExpress strains contain genetic mutations phenotypically selected for conferring tolerance to toxic proteins. The strain C41(DE3) was derived from BL21(DE3). This strain has at least one mutation, which prevents cell death associated with expression of many recombinant toxic proteins. The strain C43(DE3) was derived from C41(DE3) by selecting for resistance to a different toxic protein and can express a different set of toxic proteins to C41(DE3). Figure 1 graphically illustrates the advantages of the OverExpress Competent Cells, compared to standard BL21(DE3) cells, in expressing toxic proteins.
Product OverExpress C41(DE3) Chemically Competent Cells - 24 reactions
Company Lucigen Corporation
Price Request a quote
More Information View company product page
Catalog Number 60442-2
Quantity 24 reactions (SOLOs)
Company Logo

Lucigen Corporation
2120 West Greenview Dr., Suite 9 Middleton, WI 53562 US

Tel: +1 608 831 9011
Fax: +1 608 831 9012
Email: lucigen@lucigen.com



Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!